Because progress begins with groundbreaking products
As the leading radiopharmaceutical-focused company, we have a clear Purpose to Find, Fight and Follow® disease to deliver better patient outcomes. With expertise in the development, manufacturing and commercialization of radiopharmaceuticals and precision diagnostics, we deliver life-changing science into the hand of physicians.
Our commercial products are used by nuclear medicine physicians, oncologists, radiologists, urologists, cardiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings.
With over 3.3 million men living with prostate cancer and more than 20 million adults affected by coronary artery disease in the U.S., our portfolio becomes more vital each day.1, 2
Key Products
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions
Additional Products
aBSI
aPROMISE
NEUROLITE®
(Kit for the Preparation of Technetium Tc 99m Bicisate for Injection)
Xenon Xe-133 Gas
Our Focus
Leveraging our strong heritage and expertise in radiopharmaceuticals, we are focused on delivering innovative products to help Find, Fight and Follow disease in areas of high unmet need. We classify our products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships.
Our Radiopharmaceutical Oncology products help healthcare professionals Find, Fight and Follow cancer.
Our leading Precision Diagnostic agents assist healthcare professionals to Find and Follow diseases in the earliest stages—when it matters most.
As a partner of choice, Strategic Partnerships allow for us to collaborate with like-minded organizations across industry and academia to enable precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms.
References:
- Key Statistics for Prostate Cancer. American Cancer Society. Published January 19, 2024. Accessed May 21, 2024. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html#:~:text=Prostate%20cancer%20can%20be%20a,Survival%20Rates%20for%20Prostate%20Cancer
- Coronary Heart Disease. National Heart Lung and Blood Institute. Published December 20, 2023. Accessed May 21, 2024. https://www.nhlbi.nih.gov/health/coronary-heart-disease
Our Pipeline
Innovation is our continual search for a way to improve patients’ lives.